|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Immunomedics
Pharmacyclics
|
|
gptkbp:affiliation
|
gptkb:International_Society_for_Infectious_Diseases
gptkb:Biotechnology_Innovation_Organization
gptkb:American_Association_for_Cancer_Research
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
HIV_Medicine_Association
|
|
gptkbp:awards
|
Best Places to Work
Innovation awards
Corporate social responsibility awards
|
|
gptkbp:CEO
|
gptkb:Daniel_O'Day
|
|
gptkbp:clinicalTrials
|
Ongoing
|
|
gptkbp:communityEngagement
|
Health initiatives
Patient support programs
Educational outreach
|
|
gptkbp:employees
|
100-200
|
|
gptkbp:focus
|
Inflammation
Oncology
Hepatitis C treatment
HIV/AIDS treatment
|
|
gptkbp:founded
|
2001
|
|
gptkbp:headCoach
|
150
|
|
gptkbp:headquarters
|
gptkb:Amsterdam
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences Netherlands B.V.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:operatesIn
|
gptkb:Netherlands
|
|
gptkbp:parentCompany
|
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:partnerships
|
Various healthcare organizations
|
|
gptkbp:products
|
Antiviral drugs
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
EMA
|
|
gptkbp:researchFocus
|
Virology
Autoimmune diseases
Hematology
Liver diseases
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:sustainabilityInitiatives
|
Social responsibility
Environmental responsibility
Governance practices
|
|
gptkbp:website
|
www.gilead.com
|